Deposition, imaging, and clearance: what remains to be done?
Deposition and clearance studies are used during product development and in fundamental research. These studies mostly involve radionuclide imaging, but pharmacokinetic methods are also used to assess the amount of drug absorbed through the lungs, which is closely related to lung deposition. Radionu...
Published in: | Journal of Aerosol Medicine and Pulmonary Drug Delivery |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Mary Ann Liebert
2010
|
Subjects: | |
Online Access: | https://boris.unibe.ch/2026/ |
id |
ftunivbern:oai:boris.unibe.ch:2026 |
---|---|
record_format |
openpolar |
spelling |
ftunivbern:oai:boris.unibe.ch:2026 2023-08-20T04:07:31+02:00 Deposition, imaging, and clearance: what remains to be done? Scheuch, Gerhard Bennett, William Borgström, Lars Clark, Andy Dalby, Richard Dolovich, Myrna Fleming, John Gehr, Peter Gonda, Igor O'Callaghan, Chris Taylor, Glyn Newman, Steve 2010 https://boris.unibe.ch/2026/ eng eng Mary Ann Liebert https://boris.unibe.ch/2026/ info:eu-repo/semantics/restrictedAccess Scheuch, Gerhard; Bennett, William; Borgström, Lars; Clark, Andy; Dalby, Richard; Dolovich, Myrna; Fleming, John; Gehr, Peter; Gonda, Igor; O'Callaghan, Chris; Taylor, Glyn; Newman, Steve (2010). Deposition, imaging, and clearance: what remains to be done? Journal of aerosol medicine and pulmonary drug delivery, 23 Suppl 2, S39-57. New York, N.Y.: Mary Ann Liebert 10.1089/jamp.2010.0839 <http://dx.doi.org/10.1089/jamp.2010.0839> info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion NonPeerReviewed 2010 ftunivbern https://doi.org/10.1089/jamp.2010.0839 2023-07-31T20:24:08Z Deposition and clearance studies are used during product development and in fundamental research. These studies mostly involve radionuclide imaging, but pharmacokinetic methods are also used to assess the amount of drug absorbed through the lungs, which is closely related to lung deposition. Radionuclide imaging may be two-dimensional (gamma scintigraphy or planar imaging), or three-dimensional (single photon emission computed tomography and positron emission tomography). In October 2009, a group of scientists met at the "Thousand Years of Pharmaceutical Aerosols" conference in Reykjavik, Iceland, to discuss future research in key areas of pulmonary drug delivery. This article reports the session on "Deposition, imaging and clearance." The objective was partly to review our current understanding, but more importantly to assess "what remains to be done?" A need to standardize methodology and provide a regulatory framework by which data from radionuclide imaging methods could be compared between centers and used in the drug approval process was recognized. There is also a requirement for novel radiolabeling methods that are more representative of production processes for dry powder inhalers and pressurized metered dose inhalers. A need was identified for studies to aid our understanding of the relationship between clinical effects and regional deposition patterns of inhaled drugs. A robust methodology to assess clearance from small conducting airways should be developed, as a potential biomarker for therapies in cystic fibrosis and other diseases. The mechanisms by which inhaled nanoparticles are removed from the lungs, and the factors on which their removal depends, require further investigation. Last, and by no means least, we need a better understanding of patient-related factors, including how to reduce the variability in pulmonary drug delivery, in order to improve the precision of deposition and clearance measurements. Article in Journal/Newspaper Iceland BORIS (Bern Open Repository and Information System, University of Bern) Journal of Aerosol Medicine and Pulmonary Drug Delivery 23 S2 S-39 S-57 |
institution |
Open Polar |
collection |
BORIS (Bern Open Repository and Information System, University of Bern) |
op_collection_id |
ftunivbern |
language |
English |
description |
Deposition and clearance studies are used during product development and in fundamental research. These studies mostly involve radionuclide imaging, but pharmacokinetic methods are also used to assess the amount of drug absorbed through the lungs, which is closely related to lung deposition. Radionuclide imaging may be two-dimensional (gamma scintigraphy or planar imaging), or three-dimensional (single photon emission computed tomography and positron emission tomography). In October 2009, a group of scientists met at the "Thousand Years of Pharmaceutical Aerosols" conference in Reykjavik, Iceland, to discuss future research in key areas of pulmonary drug delivery. This article reports the session on "Deposition, imaging and clearance." The objective was partly to review our current understanding, but more importantly to assess "what remains to be done?" A need to standardize methodology and provide a regulatory framework by which data from radionuclide imaging methods could be compared between centers and used in the drug approval process was recognized. There is also a requirement for novel radiolabeling methods that are more representative of production processes for dry powder inhalers and pressurized metered dose inhalers. A need was identified for studies to aid our understanding of the relationship between clinical effects and regional deposition patterns of inhaled drugs. A robust methodology to assess clearance from small conducting airways should be developed, as a potential biomarker for therapies in cystic fibrosis and other diseases. The mechanisms by which inhaled nanoparticles are removed from the lungs, and the factors on which their removal depends, require further investigation. Last, and by no means least, we need a better understanding of patient-related factors, including how to reduce the variability in pulmonary drug delivery, in order to improve the precision of deposition and clearance measurements. |
format |
Article in Journal/Newspaper |
author |
Scheuch, Gerhard Bennett, William Borgström, Lars Clark, Andy Dalby, Richard Dolovich, Myrna Fleming, John Gehr, Peter Gonda, Igor O'Callaghan, Chris Taylor, Glyn Newman, Steve |
spellingShingle |
Scheuch, Gerhard Bennett, William Borgström, Lars Clark, Andy Dalby, Richard Dolovich, Myrna Fleming, John Gehr, Peter Gonda, Igor O'Callaghan, Chris Taylor, Glyn Newman, Steve Deposition, imaging, and clearance: what remains to be done? |
author_facet |
Scheuch, Gerhard Bennett, William Borgström, Lars Clark, Andy Dalby, Richard Dolovich, Myrna Fleming, John Gehr, Peter Gonda, Igor O'Callaghan, Chris Taylor, Glyn Newman, Steve |
author_sort |
Scheuch, Gerhard |
title |
Deposition, imaging, and clearance: what remains to be done? |
title_short |
Deposition, imaging, and clearance: what remains to be done? |
title_full |
Deposition, imaging, and clearance: what remains to be done? |
title_fullStr |
Deposition, imaging, and clearance: what remains to be done? |
title_full_unstemmed |
Deposition, imaging, and clearance: what remains to be done? |
title_sort |
deposition, imaging, and clearance: what remains to be done? |
publisher |
Mary Ann Liebert |
publishDate |
2010 |
url |
https://boris.unibe.ch/2026/ |
genre |
Iceland |
genre_facet |
Iceland |
op_source |
Scheuch, Gerhard; Bennett, William; Borgström, Lars; Clark, Andy; Dalby, Richard; Dolovich, Myrna; Fleming, John; Gehr, Peter; Gonda, Igor; O'Callaghan, Chris; Taylor, Glyn; Newman, Steve (2010). Deposition, imaging, and clearance: what remains to be done? Journal of aerosol medicine and pulmonary drug delivery, 23 Suppl 2, S39-57. New York, N.Y.: Mary Ann Liebert 10.1089/jamp.2010.0839 <http://dx.doi.org/10.1089/jamp.2010.0839> |
op_relation |
https://boris.unibe.ch/2026/ |
op_rights |
info:eu-repo/semantics/restrictedAccess |
op_doi |
https://doi.org/10.1089/jamp.2010.0839 |
container_title |
Journal of Aerosol Medicine and Pulmonary Drug Delivery |
container_volume |
23 |
container_issue |
S2 |
container_start_page |
S-39 |
op_container_end_page |
S-57 |
_version_ |
1774719197340762112 |